Feed - Buzzberg

11:30
Aug 04 ◎

RVTY FY2026 Q2 Watch

Revvity, Inc. (RVTY) FY2026 Q2 Earnings Call

ANTHROPIC RVTY ▾

Prahlad Singh

Revvity is partnering with Anthropic to integrate its LLM into the Signals platform, expanding the functionality of its software and creating stickiness for its customers; this validates Anthropic's push into scientific verticals.

"our newly introduced Anthropic MCP connector now allow scientists to close that loop in ways that were simply not possible before"

ANTHROPIC WATCH

Prahlad Singh

Management raised full-year organic growth, operating margin, and EPS guidance, citing accelerating pharma/biotech recovery and strong AI-driven demand for high-content screening and software.

"given the stronger performance and our improved optimism for the second half, we are raising our pro forma guidance for organic growth, adjusted operating margin, and adjusted EPS"

RVTY WATCH

HIGH

11:30
May 05 ◎

RVTY FY2026 Q1 Watch

Revvity, Inc. (RVTY) FY2026 Q1 Earnings Call

IT LLY RVTY SYK ▾

Prahlad Singh

Gartner published research highlighting Revvity's AI deployment, indicating a partnership or validation that could be referenced in Gartner's future reports on AI adoption.

"The well-known research firm Gartner recently published a research paper highlighting our internal AI deployment, which stands out across the industries that they've researched."

IT WATCH

Prahlad Singh

Revvity announced a partnership with Lilly to leverage its ecosystem for its new 'Synthetica' AI platform, indicating a close collaboration with the pharma giant.

"You know, we announced the Lily Tune Labs partnership, which is a great launchpad for Synthetica, leveraging the ecosystem that Lily brings to the table."

LLY WATCH

Prahlad Singh

Guidance is cautiously optimistic, with pro-forma growth of 3-4% and margin expansion driven by divesting a low-margin China business and executing on cost efficiency initiatives.

"we are now looking for organic growth of three to 4% adjusted operating margins of 28.4% and adjusted earnings per share of $5.20 to $5.30"

RVTY WATCH

Prahlad Singh

Revvity's AI strategy is based on the belief that AI-generated discoveries will create a 'demand bottleneck' for physical validation, requiring more wet lab tools and reagents, positioning them to benefit from the build-out of AI infrastructure in life sciences. — This thesis implies a secular tailwind for lab tools companies as AI accelerates the number of drug targets, potentially benefiting peers like Danaher (DHR) and Thermo Fisher (TMO).

"This inflection point sits squarely within gravity's core strengths providing the critical technologies that translate AI driven insights into real world biological validation."

SYK WATCH

HIGH

13:00
Feb 02 ◎

RVTY FY2025 Q4 Watch

Revvity, Inc. (RVTY) FY2025 Q4 Earnings Call

LLY DHR TMO VWR RVTY ▾

Prahlad Singh

Management is highlighting a major partnership with Lilly to co-fund access to its Signals platform and provide AI modeling credits, which could drive adoption and engagement.

"As part of our Zynthetica launch, we also announced our important collaboration with Lilly and its TuneLab initiative. Lilly TuneLab's AI models are built on knowledge and insight from over a billion dollars of R&D investment by the"

LLY WATCH

Prahlad Singh

Life sciences instruments saw a strong double-digit sequential revenue increase from Q3 to Q4 2025 and were roughly flat year-over-year, marking a meaningful improvement versus the significant declines seen over the prior three years. — OES demand is showing signs of stabilization and potential recovery, which is a leading indicator for the broader life sciences tools sector.

"We also saw continued improvements in demand for our life sciences instruments during the fourth quarter as they were also roughly flat on a year over year basis. This performance for our instruments represented a strong double-digit"

DHR WATCH TMO WATCH

Prahlad Singh

The company saw pharma customer organic growth of low single digits and academic/government decline of low single digits in Q4, with no budget flush observed, indicating the pharma recovery is still in early, cautious stages. — Improvement is based on policy clarity, not a burst of year-end spending, suggesting a slower, more durable recovery rather than a sharp snapback.

"I would say that overall, what we've seen is cautious optimism and consistency in terms of order trending i wouldn't say that there was a budget flush i think that's the way i would think of it"

VWR WATCH

Prahlad Singh

The company is cautious but sees multiple paths to upside from biopharma recovery, NIH clarity, and better biotech funding. The tone is cautiously optimistic, positioning for stronger performance if markets recover.

"we are reiterating for our organic growth this year to be in the 2-3% range as we are assuming recent end market trends continue over the course of the year. If these potentially favorable market conditions do result in customer demand"

RVTY WATCH

HIGH

Feed — Buzzberg